QUT researchers will fast-track research into potential new lung cancer drug treatments through a strategic collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, facilitated by the Johnson & Johnson Innovation Partnering Office.
The QUT research team, led by Professor Derek Richard, have been given access to the Janssen Jump-stARTer Compound Library, a unique and highly curated collection of 80,000 chemical compounds, which may allow the researchers to hasten identifying potential promising drug candidates and advancing their development.
Lung cancer is the fifth most commonly diagnosed cancer and the most common cause of cancer death in Australia.
Vice-President of Business Development Professor Mark Harvey welcomed the announcement and said the QUT research team would be using high-tech robotic devices to screen potential drug candidates.
“The Jump-stARTer Compound Library is a world class molecule library, and this strategic collaboration will potentially reduce the time needed to identify promising new drug candidates, it epitomises the real-world research approach at QUT,” Professor Harvey said.
“Collaborations like this, along with the use of cutting-edge robotic screening technologies, will help drive significant changes in medicine in the next few decades and we look forward to the continued opportunities our researchers will have in working on real-world projects with collaborators.”
